Send the following on WhatsApp
Continue to Chat三期臨床數據助攻 衛采旗下 Lecanemab 有望獲得優先審核 https://geneonline.news/eisai-lecanemab-fda-priority-review/?variant=zh-cn
三期臨床數據助攻 衛采旗下 Lecanemab 有望獲得優先審核 https://geneonline.news/eisai-lecanemab-fda-priority-review/?variant=zh-cn